SK284464B6 - Použitie zlúčeniny, vybranej zo skupiny, pozostávajúcej z vitamínu E a jeho esterov, na prípravu lieku na miestne liečenie patologických stavov sliznice - Google Patents
Použitie zlúčeniny, vybranej zo skupiny, pozostávajúcej z vitamínu E a jeho esterov, na prípravu lieku na miestne liečenie patologických stavov sliznice Download PDFInfo
- Publication number
- SK284464B6 SK284464B6 SK35-2001A SK352001A SK284464B6 SK 284464 B6 SK284464 B6 SK 284464B6 SK 352001 A SK352001 A SK 352001A SK 284464 B6 SK284464 B6 SK 284464B6
- Authority
- SK
- Slovakia
- Prior art keywords
- vitamin
- compound
- mucosa
- group
- medicament
- Prior art date
Links
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 title claims abstract description 45
- 238000011282 treatment Methods 0.000 title claims abstract description 34
- 229930003427 Vitamin E Natural products 0.000 title claims abstract description 21
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 title claims abstract description 21
- 229940046009 vitamin E Drugs 0.000 title claims abstract description 21
- 239000011709 vitamin E Substances 0.000 title claims abstract description 21
- 235000019165 vitamin E Nutrition 0.000 title claims abstract description 21
- 150000001875 compounds Chemical class 0.000 title claims abstract description 19
- 239000003814 drug Substances 0.000 title claims abstract description 16
- 150000002148 esters Chemical class 0.000 title claims abstract description 10
- 238000004519 manufacturing process Methods 0.000 title abstract description 3
- 230000007170 pathology Effects 0.000 title abstract 2
- 210000004877 mucosa Anatomy 0.000 claims abstract description 30
- 230000000699 topical effect Effects 0.000 claims abstract description 30
- 206010023332 keratitis Diseases 0.000 claims abstract description 24
- 208000003251 Pruritus Diseases 0.000 claims abstract description 17
- 208000003265 stomatitis Diseases 0.000 claims abstract description 16
- 230000007803 itching Effects 0.000 claims abstract description 14
- 208000001780 epistaxis Diseases 0.000 claims abstract description 13
- 206010036774 Proctitis Diseases 0.000 claims abstract description 8
- 208000034347 Faecal incontinence Diseases 0.000 claims abstract description 7
- 201000004946 genital herpes Diseases 0.000 claims abstract description 7
- 210000002200 mouth mucosa Anatomy 0.000 claims abstract description 7
- 206010003693 Atrophic vulvovaginitis Diseases 0.000 claims abstract description 6
- 208000001688 Herpes Genitalis Diseases 0.000 claims abstract description 6
- 208000004746 Atrophic Vaginitis Diseases 0.000 claims abstract description 5
- 201000007717 corneal ulcer Diseases 0.000 claims abstract description 5
- 201000010808 postmenopausal atrophic vaginitis Diseases 0.000 claims abstract description 5
- 206010068172 Anal pruritus Diseases 0.000 claims abstract description 3
- 208000009544 Pruritus Ani Diseases 0.000 claims abstract description 3
- 229940042585 tocopherol acetate Drugs 0.000 claims description 73
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 72
- 230000001575 pathological effect Effects 0.000 claims description 27
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims description 24
- 208000025865 Ulcer Diseases 0.000 claims description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 12
- 201000010666 keratoconjunctivitis Diseases 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 7
- 231100000397 ulcer Toxicity 0.000 claims description 7
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 6
- 239000013543 active substance Substances 0.000 claims description 5
- 239000003242 anti bacterial agent Substances 0.000 claims description 5
- 150000001735 carboxylic acids Chemical class 0.000 claims description 5
- 239000004615 ingredient Substances 0.000 claims description 5
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 5
- 206010036783 Proctitis ulcerative Diseases 0.000 claims description 4
- 229940088710 antibiotic agent Drugs 0.000 claims description 4
- 239000005556 hormone Substances 0.000 claims description 4
- 229940088597 hormone Drugs 0.000 claims description 4
- 201000010727 rectal prolapse Diseases 0.000 claims description 4
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 125000003342 alkenyl group Chemical group 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 229940121375 antifungal agent Drugs 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 3
- 235000020778 linoleic acid Nutrition 0.000 claims description 3
- 230000003637 steroidlike Effects 0.000 claims description 3
- 239000001384 succinic acid Substances 0.000 claims description 3
- -1 vitamin E ester Chemical class 0.000 claims description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000002294 steroidal antiinflammatory agent Substances 0.000 claims 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000002399 aphthous stomatitis Diseases 0.000 abstract description 12
- 208000002003 vulvitis Diseases 0.000 abstract description 11
- 206010039083 rhinitis Diseases 0.000 abstract description 7
- 230000005855 radiation Effects 0.000 abstract description 6
- 206010028781 Nasal vestibulitis Diseases 0.000 abstract description 3
- 230000003325 follicular Effects 0.000 abstract description 3
- 208000005232 Glossitis Diseases 0.000 abstract 1
- 201000003079 ectropion Diseases 0.000 abstract 1
- 210000000981 epithelium Anatomy 0.000 description 17
- 208000024891 symptom Diseases 0.000 description 16
- 210000001508 eye Anatomy 0.000 description 12
- 230000003902 lesion Effects 0.000 description 11
- 230000008901 benefit Effects 0.000 description 10
- 239000011248 coating agent Substances 0.000 description 10
- 238000000576 coating method Methods 0.000 description 10
- 230000004054 inflammatory process Effects 0.000 description 10
- 230000009467 reduction Effects 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 210000004379 membrane Anatomy 0.000 description 9
- 239000012528 membrane Substances 0.000 description 9
- 208000002193 Pain Diseases 0.000 description 8
- 210000004087 cornea Anatomy 0.000 description 8
- 230000008034 disappearance Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000006872 improvement Effects 0.000 description 8
- 208000014674 injury Diseases 0.000 description 8
- 150000002632 lipids Chemical class 0.000 description 8
- 210000002850 nasal mucosa Anatomy 0.000 description 8
- 230000001681 protective effect Effects 0.000 description 8
- 230000000306 recurrent effect Effects 0.000 description 8
- 210000003491 skin Anatomy 0.000 description 8
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- 206010070245 Foreign body Diseases 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000035876 healing Effects 0.000 description 6
- 210000000214 mouth Anatomy 0.000 description 6
- 239000002674 ointment Substances 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 229930003799 tocopherol Natural products 0.000 description 6
- 239000011732 tocopherol Substances 0.000 description 6
- 235000010384 tocopherol Nutrition 0.000 description 6
- 229960001295 tocopherol Drugs 0.000 description 6
- 230000008733 trauma Effects 0.000 description 6
- 206010020751 Hypersensitivity Diseases 0.000 description 5
- 206010046996 Varicose vein Diseases 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 210000003560 epithelium corneal Anatomy 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000036269 ulceration Effects 0.000 description 5
- 208000027185 varicose disease Diseases 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 230000007815 allergy Effects 0.000 description 4
- 208000010668 atopic eczema Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 210000004400 mucous membrane Anatomy 0.000 description 4
- 150000003904 phospholipids Chemical class 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000001932 seasonal effect Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 210000001215 vagina Anatomy 0.000 description 4
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 3
- 206010013774 Dry eye Diseases 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 206010067152 Oral herpes Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 239000000739 antihistaminic agent Substances 0.000 description 3
- 229940125715 antihistaminic agent Drugs 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 239000013043 chemical agent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 239000006196 drop Substances 0.000 description 3
- 230000003628 erosive effect Effects 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 210000000744 eyelid Anatomy 0.000 description 3
- 230000000642 iatrogenic effect Effects 0.000 description 3
- 210000003097 mucus Anatomy 0.000 description 3
- 238000010606 normalization Methods 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 210000000664 rectum Anatomy 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000037390 scarring Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- 230000001720 vestibular Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 239000004925 Acrylic resin Substances 0.000 description 2
- 229920000178 Acrylic resin Polymers 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 2
- 208000004483 Dyspareunia Diseases 0.000 description 2
- 239000005770 Eugenol Substances 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 208000000440 Herpetic Stomatitis Diseases 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 2
- 206010044604 Trichiasis Diseases 0.000 description 2
- 206010064996 Ulcerative keratitis Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 206010005159 blepharospasm Diseases 0.000 description 2
- 230000000744 blepharospasm Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000002573 colposcopy Methods 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229960002217 eugenol Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000000762 glandular Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 210000005075 mammary gland Anatomy 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 210000001331 nose Anatomy 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000004576 sand Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 150000003611 tocopherol derivatives Chemical class 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000027496 Behcet disease Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 206010006803 Burns third degree Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010007877 Cell-mediated immune deficiency Diseases 0.000 description 1
- 208000009043 Chemical Burns Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 208000006069 Corneal Opacity Diseases 0.000 description 1
- 206010011026 Corneal lesion Diseases 0.000 description 1
- 206010055665 Corneal neovascularisation Diseases 0.000 description 1
- 206010061908 Cranial nerve paralysis Diseases 0.000 description 1
- 241001466953 Echovirus Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010064503 Excessive skin Diseases 0.000 description 1
- 108010019393 Fibrin Foam Proteins 0.000 description 1
- 206010016880 Folate deficiency Diseases 0.000 description 1
- 208000010188 Folic Acid Deficiency Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 208000004898 Herpes Labialis Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 206010022971 Iron Deficiencies Diseases 0.000 description 1
- 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 241001313288 Labia Species 0.000 description 1
- 206010023644 Lacrimation increased Diseases 0.000 description 1
- 241001123008 Leukoma Species 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- 206010061297 Mucosal erosion Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 208000003420 Nasal Septal Perforation Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 206010036775 Rectal inflammations Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 241001134658 Streptococcus mitis Species 0.000 description 1
- 241000194023 Streptococcus sanguinis Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010056651 Vestibulitis Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 206010047791 Vulvovaginal dryness Diseases 0.000 description 1
- 206010053692 Wound complication Diseases 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000011360 adjunctive therapy Methods 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000000607 artificial tear Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004045 bowman membrane Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 239000003518 caustics Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 210000002777 columnar cell Anatomy 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000002920 convulsive effect Effects 0.000 description 1
- 201000000159 corneal neovascularization Diseases 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 201000005937 cranial nerve palsy Diseases 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000008378 epithelial damage Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000000729 hypotrophic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000005061 intracellular organelle Anatomy 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 210000004561 lacrimal apparatus Anatomy 0.000 description 1
- 230000004317 lacrimation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000000936 membranestabilizing effect Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000015689 metaplastic ossification Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 210000000492 nasalseptum Anatomy 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 230000037309 reepithelialization Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000025053 regulation of cell proliferation Effects 0.000 description 1
- 230000006833 reintegration Effects 0.000 description 1
- 230000008263 repair mechanism Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 229940125379 topical corticosteroid Drugs 0.000 description 1
- 210000003901 trigeminal nerve Anatomy 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 208000002670 vitamin B12 deficiency Diseases 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Communicable Diseases (AREA)
- Gynecology & Obstetrics (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT98MI001586A ITMI981586A1 (it) | 1998-07-10 | 1998-07-10 | Vitamina e e suoi esteri per l'uso nel trattamento topico di patologie delle mucose |
| PCT/IB1999/001238 WO2000002554A1 (en) | 1998-07-10 | 1999-07-05 | Vitamin e and esters thereof for use in the topical treatment of mucosal pathologies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SK352001A3 SK352001A3 (en) | 2001-06-11 |
| SK284464B6 true SK284464B6 (sk) | 2005-04-01 |
Family
ID=11380415
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK35-2001A SK284464B6 (sk) | 1998-07-10 | 1999-07-05 | Použitie zlúčeniny, vybranej zo skupiny, pozostávajúcej z vitamínu E a jeho esterov, na prípravu lieku na miestne liečenie patologických stavov sliznice |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP1094807B1 (https=) |
| JP (1) | JP2002520281A (https=) |
| CN (1) | CN1135975C (https=) |
| AT (1) | ATE238051T1 (https=) |
| AU (1) | AU762860B2 (https=) |
| BR (1) | BR9911945A (https=) |
| CA (1) | CA2336990A1 (https=) |
| CZ (1) | CZ301019B6 (https=) |
| DE (1) | DE69907193T2 (https=) |
| DK (1) | DK1094807T3 (https=) |
| ES (1) | ES2196813T3 (https=) |
| HU (1) | HU228921B1 (https=) |
| IL (1) | IL140759A0 (https=) |
| IT (1) | ITMI981586A1 (https=) |
| NO (1) | NO20006719L (https=) |
| NZ (1) | NZ509129A (https=) |
| PL (1) | PL345500A1 (https=) |
| PT (1) | PT1094807E (https=) |
| RU (2) | RU2221561C2 (https=) |
| SK (1) | SK284464B6 (https=) |
| TR (2) | TR200103710T2 (https=) |
| WO (1) | WO2000002554A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040077604A1 (en) | 2001-12-19 | 2004-04-22 | Lenard Lichtenberger | Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providingenhanced therapeutic activity |
| FR2819186A1 (fr) * | 2001-01-10 | 2002-07-12 | L M D | Cystine-voie orale-syndrome de l'oeil sec |
| FR2825088A1 (fr) * | 2001-05-25 | 2002-11-29 | Derma Dev | Nouveaux esters de tocopherol, leurs procedes d'obtention et leurs utilisations |
| US7485666B2 (en) * | 2004-06-17 | 2009-02-03 | Kimberly-Clark Worldwide, Inc. | Vaginal health products |
| US8541413B2 (en) * | 2004-10-01 | 2013-09-24 | Ramscor, Inc. | Sustained release eye drop formulations |
| US9993558B2 (en) | 2004-10-01 | 2018-06-12 | Ramscor, Inc. | Sustained release eye drop formulations |
| US20080038316A1 (en) | 2004-10-01 | 2008-02-14 | Wong Vernon G | Conveniently implantable sustained release drug compositions |
| AU2006220248B2 (en) * | 2005-03-03 | 2012-06-21 | Vital Health Sciences Pty Ltd | Compounds having lipid lowering properties |
| BRPI0920326A2 (pt) * | 2008-10-09 | 2016-02-23 | Ramscor Inc | composição e método para tratamento da síndrome do olho ressecado |
| IT1394063B1 (it) * | 2009-05-11 | 2012-05-25 | Giuliani Spa | Composizione per uso oftalmico adatta al trattamento degli stati infiammatori dell'occhio e della sindrome dell'occhio secco |
| US9192594B2 (en) * | 2009-07-27 | 2015-11-24 | Renato Sanseverino | Ophthalmic solution for protecting internal structures of the eyeball against UV-A rays or for the treatment of keratoconus with a trans-epithelial cross-linking technique |
| CN103957888B (zh) | 2011-09-29 | 2017-11-21 | PLx 制药公司 | 用于将药物沿胃肠道靶向释放的pH依赖性载体、其组合物及其制备和应用 |
| WO2013185024A1 (en) * | 2012-06-08 | 2013-12-12 | The Ohio State University | Treating burn and scar injury using tocotrienol |
| DE202014106007U1 (de) * | 2014-07-22 | 2015-07-23 | Bio.Lo.Ga. S.R.L. | Zusammensetzung zur Verwendung in der Vorbeugung und Behandlung allergischer Rhinitis |
| CN107438429A (zh) * | 2014-10-22 | 2017-12-05 | 拜洛嘉有限责任公司 | 用于增加鼻粘膜的营养作用的药物组合物 |
| JP2018507895A (ja) | 2015-03-18 | 2018-03-22 | バイオヌークス スイス エスエー | ヘルペスを処置するための方法において使用するためのジヒドロケルセチンを含む組成物 |
| JP2017119669A (ja) * | 2015-10-15 | 2017-07-06 | ロート製薬株式会社 | 異物感改善用眼科組成物 |
| EP3849514A1 (en) * | 2018-09-12 | 2021-07-21 | Neilos S.r.l. | A composition for use in the prevention and/or treatment of epistaxis |
| IT202000003620A1 (it) * | 2020-02-21 | 2021-08-21 | Hulka S R L | Uso di una formulazione per applicazione topica per il mantenimento dell’omeostasi vaginale |
| AU2021244695A1 (en) | 2020-03-26 | 2022-11-10 | Plx Opco Inc. | Pharmaceutical carriers capable of pH dependent reconstitution and methods for making and using same |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59216812A (ja) * | 1983-05-26 | 1984-12-06 | Dowa Yakushiyou Kk | 頭髪育毛料 |
| JP2776837B2 (ja) * | 1988-08-11 | 1998-07-16 | 日本レダリー株式会社 | 消化性潰瘍治療剤 |
| US5032384A (en) * | 1989-01-27 | 1991-07-16 | Block Drug Company, Inc. | Compositions and method for the treatment of disease |
| SU1628281A3 (ru) * | 1989-03-30 | 1994-02-28 | Научно-производственная фирма "Флори" | Ранозаживляющее средство |
| IT1249711B (it) * | 1991-09-30 | 1995-03-09 | Boniscontro E Gazzone S R L | Composizioni farmaceutiche, per uso topico, contenenti "scavengers" di radicali liberi dell'ossigeno e antibatterici,indicate nella terapia dei tessuti superficiali. |
| JP2811036B2 (ja) * | 1992-05-26 | 1998-10-15 | 参天製薬株式会社 | ビタミンｅ点眼剤 |
| JP3551977B2 (ja) * | 1993-04-08 | 2004-08-11 | ライオン株式会社 | 安定なビタミンａ類及びビタミンｅ類可溶化点眼剤 |
| CN1039087C (zh) * | 1993-12-29 | 1998-07-15 | 昆明宏达实业有限总公司 | 妇科病治疗保健外用药物 |
| RU2125887C1 (ru) * | 1995-08-25 | 1999-02-10 | Владивостокский государственный медицинский университет | Способ приготовления липосомального интерферона |
| IT1282778B1 (it) * | 1996-05-31 | 1998-03-31 | Giorgio Panin | Vitamina "e" acetato quale prodotto per applicazione topica |
| JPH10109934A (ja) * | 1996-10-04 | 1998-04-28 | Sekisui Chem Co Ltd | 炎症性眼疾患用剤 |
| JPH10231243A (ja) * | 1997-02-20 | 1998-09-02 | Sekisui Chem Co Ltd | 粘膜炎症外用薬 |
-
1998
- 1998-07-10 IT IT98MI001586A patent/ITMI981586A1/it unknown
-
1999
- 1999-07-05 HU HU0102781A patent/HU228921B1/hu unknown
- 1999-07-05 EP EP99926687A patent/EP1094807B1/en not_active Expired - Lifetime
- 1999-07-05 IL IL14075999A patent/IL140759A0/xx unknown
- 1999-07-05 RU RU2001101122/15A patent/RU2221561C2/ru active
- 1999-07-05 DE DE69907193T patent/DE69907193T2/de not_active Expired - Lifetime
- 1999-07-05 BR BR9911945-5A patent/BR9911945A/pt not_active Application Discontinuation
- 1999-07-05 JP JP2000558814A patent/JP2002520281A/ja active Pending
- 1999-07-05 PL PL99345500A patent/PL345500A1/xx not_active Application Discontinuation
- 1999-07-05 PT PT99926687T patent/PT1094807E/pt unknown
- 1999-07-05 TR TR2001/03710T patent/TR200103710T2/xx unknown
- 1999-07-05 NZ NZ509129A patent/NZ509129A/en not_active IP Right Cessation
- 1999-07-05 CA CA002336990A patent/CA2336990A1/en not_active Abandoned
- 1999-07-05 AT AT99926687T patent/ATE238051T1/de active
- 1999-07-05 CN CNB998084328A patent/CN1135975C/zh not_active Expired - Lifetime
- 1999-07-05 TR TR2001/00014T patent/TR200100014T2/xx unknown
- 1999-07-05 WO PCT/IB1999/001238 patent/WO2000002554A1/en not_active Ceased
- 1999-07-05 DK DK99926687T patent/DK1094807T3/da active
- 1999-07-05 AU AU43858/99A patent/AU762860B2/en not_active Expired
- 1999-07-05 SK SK35-2001A patent/SK284464B6/sk unknown
- 1999-07-05 ES ES99926687T patent/ES2196813T3/es not_active Expired - Lifetime
- 1999-07-05 CZ CZ20010036A patent/CZ301019B6/cs unknown
-
2000
- 2000-12-29 NO NO20006719A patent/NO20006719L/no not_active Application Discontinuation
-
2003
- 2003-09-11 RU RU2003128023/15A patent/RU2003128023A/ru not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000002554A1 (en) | 2000-01-20 |
| AU4385899A (en) | 2000-02-01 |
| CN1135975C (zh) | 2004-01-28 |
| CZ301019B6 (cs) | 2009-10-14 |
| DE69907193D1 (de) | 2003-05-28 |
| CZ200136A3 (cs) | 2001-08-15 |
| ATE238051T1 (de) | 2003-05-15 |
| HU228921B1 (en) | 2013-06-28 |
| CN1308531A (zh) | 2001-08-15 |
| NO20006719D0 (no) | 2000-12-29 |
| AU762860B2 (en) | 2003-07-10 |
| JP2002520281A (ja) | 2002-07-09 |
| TR200103710T2 (tr) | 2002-06-21 |
| TR200100014T2 (tr) | 2001-06-21 |
| RU2221561C2 (ru) | 2004-01-20 |
| NO20006719L (no) | 2001-02-16 |
| DE69907193T2 (de) | 2004-04-08 |
| ES2196813T3 (es) | 2003-12-16 |
| NZ509129A (en) | 2003-10-31 |
| SK352001A3 (en) | 2001-06-11 |
| EP1094807A1 (en) | 2001-05-02 |
| DK1094807T3 (da) | 2003-08-11 |
| IL140759A0 (en) | 2002-02-10 |
| PT1094807E (pt) | 2003-08-29 |
| PL345500A1 (en) | 2001-12-17 |
| HUP0102781A2 (hu) | 2001-12-28 |
| BR9911945A (pt) | 2001-03-27 |
| ITMI981586A1 (it) | 2000-01-10 |
| ITMI981586A0 (it) | 1998-07-10 |
| EP1094807B1 (en) | 2003-04-23 |
| RU2003128023A (ru) | 2005-04-10 |
| CA2336990A1 (en) | 2000-01-20 |
| HUP0102781A3 (en) | 2002-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK284464B6 (sk) | Použitie zlúčeniny, vybranej zo skupiny, pozostávajúcej z vitamínu E a jeho esterov, na prípravu lieku na miestne liečenie patologických stavov sliznice | |
| JP5118633B2 (ja) | 医療用デバイスおよび医薬製剤において有用な粘膜付着性キシログルカン含有製剤 | |
| WO2012092375A1 (en) | Method for treating dry eye | |
| WO2012092378A1 (en) | Method for treating blepharitis | |
| BRPI1010325B1 (pt) | composição dermatológica e/ou farmacêutica, dispositivo médico e seus usos | |
| KR101067443B1 (ko) | 하이드록시클로로퀸을 함유하는 치핵 치료를 위한 국소투여용 주사제 조성물 | |
| CN107961232A (zh) | 药物调配物和其用途 | |
| US5134165A (en) | Method of treatment for loss of vision due to ophthalmic surgery | |
| MXPA01000368A (en) | Vitamin e and esters thereof for use in the topical treatment of mucosal pathologies | |
| US20190216769A1 (en) | Topical Application of Delphinidin Compounds Treats Rosacea | |
| EP0078533B1 (en) | Medicinal composition for treating skin disorders | |
| EA002267B1 (ru) | Ранозаживляющий, противовоспалительный и противоинфекционный лекарственный препарат | |
| ROTARU et al. | NOVELTIES IN THE MANAGEMENT OF ROSACEA. | |
| Warren et al. | Geriatric Dermatologic Disorders | |
| KR20240130701A (ko) | 알라닐-글루타민 및 알라닐-글루타민을 포함하는 안과용 조성물의 새로운 용도 | |
| CA1184121A (en) | Treatment of acne and perioral dermatitis as well as for skin infected with a herpesvirus | |
| JP2004059440A (ja) | 肌荒れ防止および粘膜修復剤 | |
| CA1260397B (en) | Treatment of acne and perioral dermatitis as well as for skin infected with a herpesvirus | |
| Al-Niaimi et al. | Pre-existing and coincidental skin disease | |
| UA150749U (uk) | Спосіб одержання фармацевтичної композиції для інтраназального введення | |
| Serbelloni et al. | Pruritus Ani | |
| JP2004175808A (ja) | 有効成分としてリン酸ヒスタミンを用いて損傷組織を局所的に治療するための方法および組成物 | |
| CA2591352A1 (en) | Treatment for herpes simplex virus and other infectious diseases | |
| CN1748685A (zh) | 治疗鼻息肉和鼻息肉病的奥苯达唑鼻腔凝胶剂 |